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Cognitive Factors for Predicting Treatment Response 
in Schizophrenic Patients: One-Year Follow-Up Study 
 
 
 
ObjectiveᄏThis study was conducted to investigate the cognitive factors that can longi-
tudinally predict the response to treatment in patients with schizophrenia. 
MethodsᄏThe subjects were 49 patients with schizophrenia who were newly hospitalized 
in an acute psychiatry ward and had not been treated with medication for at least 8 weeks 
prior to the study. The symptoms and cognitive functions of the patients were evaluated at 
baseline before treatment (T0), at eight weeks after treatment (T1), and one year after 
treatment (T2). Clinical symptoms were assessed using the PANSS, and cognitive functions 
were estimated using the Vigilance Test, Cognitrone Test, Wisconsin Card Sorting Test 
(WCST), and the Korean version of the Memory Assessment Scales (K-MAS). 
ResultsᄏThe patient group showed marked impairments in cognitive function when com-
pared to the normal group, but the patients’ clinical symptoms and cognitive functions 
improved after drug treatment. The patients also showed consistent improvement in verbal 
and nonverbal memory function as time progressed. Furthermore, there was a significant 
correlation between clinical symptoms and cognitive functions in the patient group. The 
cognitive variables that best predicted treatment response and prognosis were total errors 
on the WCST and immediate list recall component of the K-MAS. It was also shown that 
the number of total errors on the WCST was a better cognitive predictor than the number 
of errors in immediate recall. 
ConclusionᄏThe results of the present study show that the neurocognitive functions of 
patients with schizophrenia can be stabilized with treatment intervention, that treatment 
response is related to improvement in cognitive function, and that cognitive domains, es-
pecially executive function, can predict treatment response and prognosis in patients with 
schizophrenia. 
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Introduction 
 
A number of studies have considered cognitive deficits to be an essential feature
of schizophrenia.
1 Several studies have reported that cognitive functioning deteriorates
over time in patients with schizophrenia,
2-5 while other studies have stated that cog-
nitive functioning can change over time and significantly improve as clinical symp-
toms stabilize.
6-8 Two hypotheses have been proposed regarding whether cognitive
performance in schizophrenia is stable over time or fluctuates throughout the course 
of the illness. The trait hypothesis suggests that abnormalities in cognitive functioning
are relatively stable and are caused by structural abnormalities in the brain, whereas
the state hypothesis proposes that cognitive deficits are changeable because they are 
based on a neurochemical or neurophysiological disturbance. It is, however, more
reasonable to combine these two hypotheses and suggest that cognitive function de-
clines as schizophrenia progresses but that it can change according to the acute dete- 
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rioration and treatment of psychosis.
9 
The relationship between symptoms and cognitive 
impairment is also an issue. A few studies have noted 
that although cognitive function in patients with schizo-
phrenia did not improve significantly during treatment, 
the patients’ clinical symptoms could be improved,
10,11 
while other studies reported that specific symptoms or 
groups of symptoms are related to a particular cognitive 
impairment.
12,13 Censits et al.
14 observed cognitive deficits 
in a group of schizophrenia patients over a period of 19 
months and concluded that cognitive deficit patterns are 
stable, while improvement in clinical symptoms, especi-
ally negative symptoms, is significantly correlated with 
enhancement in neuropsychological performance. Hoff 
et al.
15 also found a significant correlation between im-
provement of cognitive functions and decline of positive 
symptoms. 
A number of studies have also investigated the course 
of schizophrenia and sought to identify predictors of 
treatment outcome. Some studies suggested that neuro-
cognitive tests could be used to predict prognosis or the 
future effect of treatment in patients with schizophre-
nia.
16-19 Robinson et al.
18 concluded that the treatment 
response of schizophrenia patients could be predicted by 
using attention and motor vulnerability. Smith et al.
17 
demonstrated that poor performance on the Trail-Making 
Test predicted poor treatment response, and Chen et al.
19 
stated that perseverative errors on the Wisconsin Card 
Sorting Test (WCST) predicted the possibility of relapse. 
The identification of cognitive predictors would aid in 
the development of treatment strategies for improving 
the progression of the illness. Moreover, it is beneficial 
to examine cognitive factors, as these have been closely 
linked to the enhancement of psychosocial functions, 
such as social problem solving, social skill learning, and 
adjustment to the local community.
20,21 
The aims of this study were to explore longitudinal 
clinical symptoms and cognitive functioning in patients 
with schizophrenia, to identify specific cognitive domains 
in patients with schizophrenia and to clarify whether 
cognitive functioning deteriorated over time or whether 
it improved and stabilized after treatment. 
 
Methods 
 
Subjects 
Forty-nine of the schizophrenia patients who were re-
cently admitted to our acute psychiatric unit met the Di-
agnostic and Statistical Manual of Mental Disorders IV 
(DSM-IV) criteria for schizophrenia and were neurolep-
tic-free for at least 8 weeks (including 23 neuroleptic-
naive, first onset patients) were included in this study. 
The patients were assessed using the Structured Clinical 
Interview for DSM-IV Axis I Disorders (SCID-I).
22 The 
exclusion criteria included: a) patients with an organic 
mental disorder, a neurological disorder, epilepsy, brain 
damage, mental retardation, or a history of substance 
abuse; b) patients who had corrected eyesight under 0.5 
or who had impaired hearing or motor function; c) pa-
tients who had an impulse regulation problem or who we-
re non-cooperative. To rule out the effects of education 
and age on neurocognitive assessment, the subjects were 
limited to high school graduates between the ages of 18 
and 49 years. A total of 49 patients were included in the 
study, and all participants provided written informed 
consent. 
Forty-nine patients were included in the reassessment 
analysis after an eight-week interregnal period, and 34 
of these were re-examined after one year. At the 8-week 
point, 27 patients were medicated with risperidone (mean 
6 mg; range, 4-10 mg), 16 patients with amisulpride 
(mean, 600 mg; range, 400-1,200 mg), and 6 patients 
with aripiprazole (mean, 20 mg; range, 15-30 mg). Thirty-
four patients completed the one-year follow-up, and 20 
of them were being treated with risperidone (mean 5.5 
mg; range, 2-8 mg), 10 patients with amisulpride (me-
an, 450 mg; range, 200-800 mg), and 4 patients with 
aripiprazole (mean, 20 mg; range, 15-30 mg). 
A total of 100 normal control subjects were recruited. 
The normal controls were matched with the patients for 
gender, age and education. They were recruited though 
advertisement and were screened using the SCID-I, non-
patient version. None of the patients had a medical/psy-
chiatric illness or family history of mental illness in first- 
and second-degree relatives. They received a modest fee 
(70 dollars) for completing the interview and neuropsy-
chological tests. Table 1 shows the demographic data of 
both groups. This study was approved by the Institution-
al Review Board of Korea University, Ansan Hospital. 
 
Assessments 
The neuropsychological tests were assessed by a clin-
ical psychologist who had more than one year of experi-
ence with the tests. Cognitive evaluations were conducted 
three times before antipsychotic treatment (T0), after 
eight weeks (T1) and one year (T2) of receiving antipsy-
chotic drugs, and included the Vigilance Test, Cognitrone 
Test, Korean version of Memory Assessment Scales (K-
MAS), and WCST. At the same time, the patients’ clin-
ical symptoms were assessed using the Positive And 
Negative Syndrome Scale (PANSS).
23 
The Vigilance test is a subtest included in the Vienna 
Test System (PC/S Vienna Test System)
24,25 that is used 
to measure sustained attention and vigilance. The Cog- 
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nitrone test, another subtest of the Vienna Test System, 
is a complex task evaluating attention, perception, cog-
nitive flexibility, figure perception, short-term memory, 
and stress endurance. 
The K-MAS is the Korean version of the MAS, as 
translated and standardized by Lee et al.,
26 and it is re-
ported to have a high subtest reliability (.85-.91) and 
test-retest reliability (.62-.88). The MAS,
27 originally 
referred to as the Vermont Memory Scale (VMS), is used 
to assess memory function in normal and clinical groups.
28 
It has been reported to compensate for the limitations of 
other memory tests.
29 This test evaluates three domains 
of memory: 1) attention, concentration, short-term mem-
ory; 2) learning and immediate memory; and 3) delayed 
memory. 
The WCST is a representative neuropsychological test 
used to measure executive function. The WCST requires 
the development and maintenance of precise problem 
solving strategies under various test conditions. This 
study uses the WCST Computer Version-2 developed by 
Heaton.
30 
 
Statistical analysis 
First, the neurocognitive function of the patients was 
compared with that of the normal group. Second, the 
effect of drug treatment on cognitive functioning and clin-
ical symptoms of the patients was evaluated, and cog-
nitive function was correlated with clinical symptoms. 
Third, the patient group was divided into responders and 
non-responders on the basis of clinical symptom relief 
in order to identify cognitive variables that may discrim-
inate between responders and non-responders after one 
year. A 20 percent improvement in PANSS score was 
used as the criterion for improvement in clinical symp-
toms in accordance with the report by Stip et al.
31 
Statistical analysis was carried out using SPSS 10.0 and 
statistical methods, such as repeated-measure ANOVA, 
t-test, correlational analysis, and discriminant analysis. 
 
Results 
 
Cognitive functioning in patients with schizoph-
renia and normal controls 
The cognitive function scores of the patients and nor-
mal controls were compared (Table 2). The two groups 
showed significant differences in all scores of cognitive 
function, except for the short-term memory component 
of the K-MAS and the total number of correct categori-
zations in the WCST. The results showed that cognitive 
function was remarkably degraded in the patient group. 
 
Changes in cognitive functions and clinical 
symptoms in schizophrenia 
The changes in the clinical symptoms and cognitive 
functioning of the patients were examined during the pe-
riod of T0-T2. The patients showed significant differences 
in all clinical symptoms, including positive, negative, 
and general symptoms, as well as PANSS total scores 
during T0-T2 (F=35.68, p<.001; F=7.76, p<.001; F= 
19.22, p<.001; F=24.91, p<.001). 
Clinical symptoms at T0-T1 and T0-T2 were compared 
respectively. The results indicated that the total score, 
positive scale, negative scale and general scale of the 
PANSS showed greater improvement at T1 than at T0 
(t=10.07, p<.001; t =12.39, p<.001; t =5.01, p<.001; 
t=9.58, p<.001). In addition, all symptoms, except for 
the negative symptoms (t=2.02, ns), were significantly 
improved at T2 in comparison to T0 (t=4.46, p<.001; 
t=6.51, p<.001; t=3.76, p<.01). 
The changes in cognitive functioning over time were 
also analyzed (Table 3). Between T0 and T2, there were 
significant differences in the scores on the immediate 
list recall, immediate prose memory, and delayed name-
face recall components of the K-MAS, but not in any of 
the other cognitive function assessments. Continuous eval-
uation of cognitive functioning throughout the treat-
ment period showed that the subjects performed better 
TABLE 1. Demographic data for patients with schizophrenia and
normal controls (mean±SD) 
 
Schizophrenia 
(N=49) 
Normal control 
(N=100) 
Age (years) 31.39±8.32 29.69±8.91 
Education (years) 12.69±1.57 13.29±2.29 
Sex    
Male 24  (49%) 55  (55%) 
Female 25  (51%) 44  (44%) 
Age of onset  28.16±07.95  
Duration of illness 
(months) 
48.36±49.30 
 
 
Numbers of previous 
admission (n) 
00.60±00.80 
 
 
Family history (yes/no) 11/38   
Medication status on 
admission 
  
Drug-naive 23   
Drug-free for 8 
weeks 
26 
 
 
Subtype    
Paranoid 42  (85.7%)  
Undifferentiated 7  (14. 3%)  
PANSS scores     
Positive scale  23.82±04.64  
Negative scale  20.23±07.40  
General scale  43.58±10.34  
PANSS: Positive And Negative Syndrome Scale 
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on list learning, immediate list recall, delayed list recall, 
immediate prose memory, delayed prose memory, imme-
diate name-face recall, delayed name-face recall, imme-
diate visual recognition, verbal memory, visual memory 
and global memory components of the K-MAS and non-
perseverative errors on the WCST at T1 than at T0. The 
patients showed greater improvement on memory asse-
ssments, such as the immediate list recall, delayed list 
recall, immediate prose memory, delayed prose memory 
and delayed name-face recall components of the K-
MAS, at T2 in comparison to T0. 
 
Correlation between clinical symptoms and 
cognitive functions 
The short-term memory component of the K-MAS and 
the total number of correct answers on the WCST were 
significantly correlated with positive symptoms (r=0.53, 
p<0.05; r=0.53, p<0.05). Total errors and nonpersever-
ative errors on the WCST were significantly correlated 
with general symptoms (r=0.56, p<0.05; r=0.51, p< 
0.05). Nonperseverative errors on the WCST were also 
correlated with negative symptoms (r=0.51, p<0.05). 
Comparisons of cognitive function between 
treatment responders and non-responders 
To investigate the predictive value of cognitive function 
in the progression of symptoms, the patient group was 
divided into treatment responders (n=20) and non-res-
ponders (n=14) at T2. The patients who were improved 
more than 20 percents in PANSS total score were classi-
fied as responders. The Kolmogorov-Smirnov test was 
applied to test for a normal distribution, and since it was 
demonstrated that distributions of two data were nor-
malized, a parametric method was applicable. 
Comparing cognitive functions between responders and 
non-responders at T0, responders showed significantly 
poorer performances in total correct answers, persevera-
tive responses, perseverative errors, nonperseverative er-
rors, conceptual level responses, and the number of ca-
tegory completed of WCST than non-responders (t=5.17, 
p<0.001; t =3.09, p<0.05; t=3.93, p<0.01; t=3.60, p< 
0.01; t=-2.67, p<0.05; t=-2.96, p<0.05). Comparing 
cognitive functions of responders with those of non-res-
ponders at T0-T2, significant differences appeared in 
immediate list recall, delayed list recall, immediate prose 
TABLE 2. Comparisons of cognitive functions between schizophrenia patients and normal controls
Schizophrenia (N=49) Normal  controls  (N=100) 
 
M SD  M  SD 
T p 
Vigilance no. correct  082.19 21.68  095.75 10.16  -4.08** 0.000 
Cognitrone no. correct  171.93  27.88  185.66  08.31  -3.34** 0.002 
K-MAS            
List learning  049.46 12.60  059.43  07.96  -5.05** 0.000 
Immediate list recall  008.93  02.80  011.00  01.38  -4.86** 0.000 
Delayed list recall  009.14  02.66  011.31  01.20  -5.43** 0.000 
Immediate prose memory  004.44  02.23  006.68  01.97  -6.21** 0.000 
Delayed prose memory  004.51  02.31  006.70  01.98  -6.00** 0.000 
Immediate name face recall  014.57  04.34  017.55  02.45  -4.46** 0.000 
Delayed name face recall  007.68  02.59  009.33  01.15  -4.19** 0.000 
Immediate visual recognition  014.26  03.88  017.86  02.19  -6.02** 0.000 
Delayed visual recognition  016.32  02.58  018.28  01.46  -4.92** 0.000 
Short-term memory  099.91 21.21  096.71 15.15  -0.94** ns 
Verbal memory  086.00 18.23  100.19  13.46  -4.83** 0.000 
Visual memory  086.51 17.52  103.32  10.77  -6.16** 0.000 
Global memory  084.13 17.90  101.42  11.47  -6.11** 0.000 
WCST            
Total correct  065.10 17.76  070.19  08.71  -1.87** ns 
Total error  051.31 27.40  023.33 15.77  -6.56** 0.000 
Perseverative response  028.77 29.12  012.31  08.93  -3.82** 0.000 
Perseverative error  024.08 21.20  011.14  07.32  -4.11** 0.000 
Nonperseverative error  027.22 20.99  012.19 10.04  -4.70** 0.000 
Conceptual level response  050.43 24.57  065.46  09.48  -4.09** 0.000 
Categories completed  003.64  02.36  005.64  01.07  -5.58** 0.000 
Trials to 1st category  042.50 44.52  016.45 14.50  -3.95** 0.000 
*p<0.01, **p<0.001. K-MAS: Korean version of the Memory Assessment Scales, WCST: Wisconsin Card Sorting Test 
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recall, and delayed name-face recall components of K-
MAS  (F=7.96, p<0.05; F =6.78,  <0.05; F =4.71, p< 
0.05; F=7.39, p<0.05), and a significant interaction ef-
fect was revealed in total errors in the WCST (F=4.72, 
p<0.05) (Table 4). 
 
Discriminant analysis between responders and 
non-responders 
Discriminant analysis was carried out to identify the 
cognitive domain most predictive of clinical improvement 
at T2. The changes in cognitive functioning were cal-
culated following this formula: score at T0 minus score 
at T2. A total of 34 patients were analyzed. Of all the 
tests of cognitive functioning, the total number of errors 
on the WCST and the immediate list recall component 
of the K-MAS were most predictive of responder status, 
and the total number of errors on the WCST was the 
most important predictor (Table 5). 
A single classification function was computed, and 
the result showed significant differences between res-
ponders and non-responders (Chi-square=13.004, df=2, 
p<0.01). A canonical correlation score of 0.833 demon-
strated the high discriminant ability of this function. The 
immediate list recall component of the K-MAS was po-
sitively correlated with the discriminant function score. 
Therefore, it was supposed that the better list recall 
function, the better response. The total number of errors 
on the WCST was also negatively correlated with the 
discriminant function score, indicating that many errors 
in executive function might be associated with little im-
provement in clinical symptoms (Table 5). The classifi-
cation function successfully predicted 82.4% of the patients’ 
respondent status, correctly classifying 80% of respon-
ders and 85.7% of non-responders. Therefore, it was shown 
that the total number of errors on the WCST and the im-
mediate list recall component of the K-MAS might dis-
criminate between responders and non-responders. 
 
Discussion 
 
Our results were consistent with the notion that cog-
nitive dysfunction in patients with schizophrenia remains 
TABLE 3. Mean and SD of cognitive scores in schizophrenia patients (N=34)
T0 T1  T2 
 
M SD M SD M  SD 
F p 
Vigilance no. correct  89.57  11.71  087.50 11.54 085.35 15.09 0.452** ns 
Cognitrone no. correct  172.21  36.36  182.42  12.75  157.28  56.21  1.420** ns 
K-MAS                
List learning  045.57 13.23 053.35  08.93  050.78 11.78 2.700** ns 
Immediate list recall  007.68  02.98  009.18  01.90  009.37  01.92 6.42**0 0.005 
Delayed list recall  007.93  02.64  009.06  02.37  009.37  02.39 2.330** ns 
Immediate prose memory  004.43  02.78  004.75  02.62  005.81  02.16 3.46*** 0.044 
Delayed prose memory  04.50  02.87  005.43  02.60  005.75  02.38 1.570** ns 
Immediate name face recall  013.75  03.78  015.50  02.92  014.87  03.68 1.910** ns 
Delayed name face recall  006.93  02.46  008.25  01.43  008.37  01.54 7.18**0 0.003 
Immediate visual recall  015.00  03.34  016.18  03.70  015.25  02.97 0.980** ns 
Delayed visual recall  016.12  02.44  016.50  01.78  015.93  02.88 0.430** ns 
Short-term memory  099.50 20.90 099.00 17.58 096.78 14.76 0.150** ns 
Verbal memory  083.00 18.53 086.50 16.78 086.42 14.29 0.440** ns 
Visual memory  087.50 15.96 094.57 19.65 080.21 20.49 3.020** ns 
Global memory  082.57 17.07 089.35 20.30 079.07 16.68 2.340** ns 
WCST                
Total correct  067.14 17.19 065.57 11.92 071.50 10.45 1.300** ns 
Total error  041.93 27.19 047.93 28.68 037.66 24.41 1.060** ns 
Perseverative response  023.93 27.21 035.00 25.03 023.50 15.10 1.720** ns 
Perseverative error  020.12 20.07 029.12 19.76 019.25 13.04 1.730** ns 
Nonperseverative error  025.18 23.82 021.25 12.87 016.81 14.46 1.410** ns 
Conceptual level response  057.40 22.17 049.60 20.26 059.53 16.54 1.930** ns 
Categories completed  004.40  02.32  003.73  02.34  004.46  01.95 1.310** ns 
Trial to 1st category  040.06 44.87 028.53 34.10 024.46 27.06 0.940** ns 
*p<0.05, **p<0.01. T0: before antipsychotic treatment, T1: eight weeks after treatment, T2: one year after treatment, K-MAS: Korean 
version of the Memory Assessment Scales, WCST: Wisconsin Card Sorting Test 
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relatively static for the first few years after onset.
32-34 
This suggests that the cognitive dysfunction in patients 
with schizophrenia bears greater resemblance to a neu-
rodevelopmental model than a neurodegenerative model 
and that the neuropsychological deficits in patients with 
schizophrenia are more stable than a neurodegenerative 
model would suggest. In addition, we observed consistent 
improvement in memory function over time. Understand-
ing conversation and memorizing names and faces are 
essential to basic social adjustment, and our result de-
monstrated that medication had a positive effect on func-
tional living in patients with schizophrenia. 
Improvements in cognitive abilities, such as memory 
and executive function, were significantly correlated with 
the enhancement of clinical symptoms in patients with 
schizophrenia. These results confirmed that clinical symp-
toms and cognitive functions could be changed and en-
hanced by medication, and that the changes in symp-
toms and cognitive functions were not independent of 
each other, and acted reciprocally. In the present study, 
executive functioning showed significant correlations with 
positive, negative, and general symptoms. Stordal et al.
35 
showed that the general symptoms of schizophrenia were 
TABLE 4. Mean and SD of clinical and cognitive scores between responders and non-responders
Responders (N=20) Non-Responders  (N=14) 
T0 T2  T0  T2  Variables 
Mean  SD  Mean SD  Mean  SD Mean SD 
PANSS                
Positive scale  023.60  05.94  013.30  04.16  024.14  02.03  017.42  04.42 
Negative scale  021.10  08.07  014.30  05.03  019.00  06.73  020.00  02.44 
General scale  047.40 12.10  027.80  06.63  038.14  02.60  039.00  03.46 
Total score  092.10 24.63  055.40 12.64  081.28  09.30  076.42  07.20 
Vigilance no. correct  085.71 14.77  079.42 18.66  093.42  06.65  091.28  07.95 
Cognitrone no. correct  163.50  44.53  178.00  09.69  181.57  18.73 137.14 76.12 
K-MAS                
List learning  043.22 10.72  049.44 13.26  048.57 15.04  050.71 14.25 
Immediate list response  006.67  03.04  009.44  02.06  009.00  02.51  009.28  01.88 
Delayed list recall  007.67  02.44  009.22  02.43  008.28  03.03  009.57  02.50 
Immediate prose  004.11  02.84  005.67  02.17  004.85  02.85  006.00  02.30 
Delayed prose  004.11  02.93  005.33  02.39  005.00  02.94  006.28  02.43 
Immediate name face R  013.22  04.73  014.00  04.33  014.42  02.22  016.00  02.51 
Delayed name face R  006.00  02.69  007.67  01.65  008.14  01.57  009.28  00.75 
Visual recognition  004.77  01.92  003.11  02.75  005.71  02.05  004.57  03.55 
Short-term memory  099.22 20.17  096.00  09.74 103.57 22.60  095.28 19.18 
Verbal memory  078.11 17.56  088.00 14.49  086.00 19.35  083.14 14.76 
Visual memory  083.44 14.73  077.00 19.51  091.57 15.57  082.57 19.87 
Total memory  077.11 14.02  078.11 18.58  086.85 19.35  078.71 12.69 
WCST                
Total correct  063.87 20.23  064.62 10.46  073.14 12.19  076.00 10.70 
Total error  060.25 24.67  040.75 29.02  021.00  07.50  034.14 19.51 
Perseverative response  023.62 14.01  021.87 16.77  011.14  04.29  024.00 14.94 
Perseverative error  020.75  09.48  019.37 14.00  009.71  02.81  021.00 12.78 
Nonperseverative error  039.50 26.67  021.37 18.33  011.28  06.44  013.14  08.21 
Conceptual level response  047.37 25.52  052.62 17.19  068.85 10.02  067.42 12.55 
Categories completed  003.25  02.65  004.00  02.32  005.71  00.75  005.00  01.41 
Trial to 1st category  059.00 55.30  025.12 32.80  018.42 10.29  023.71 21.25 
T0: before antipsychotic treatment, T2: one year after treatment, PANSS: Positive And Negative Syndrome Scale, K-MAS: Korean 
version of the Memory Assessment Scales, WCST: Wisconsin Card Sorting Test 
 
TABLE 5. Discriminant analysis between responders and non-
responders 
Subtest 
Wilk’s 
Lambda 
Coefficient F  value  Significance 
Total errors  .423  -.638 16.34 .002 
Immediate 
list recall 
.635 
 
-.874 
 
06.891 
 
.020 
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predictive of impairment in executive functioning. In this 
study, there was also a correlation between the total and 
nonperseverative errors on the WCST and general symp-
toms on the PANSS. However, other studies have sugge-
sted that executive function damage was highly relevant 
to negative symptoms of schizophrenia
36-38 and aggravated 
social and occupational functions.
39-42 It is also known 
that memory ability is significantly correlated with ne-
gative symptoms rather than positive symptoms.
43,44 Most 
studies suggested that negative symptoms better explained 
cognitive impairments than positive symptoms. This study 
also found a lack of improvement in executive function 
and negative symptoms longitudinally. It did, however, 
identify significant correlations between negative symp-
toms and nonperseverative errors on the WCST for a 
short time. These results partially support those of pre-
vious studies. 
The negative symptoms of schizophrenia include de-
creased ability to perform normal daily activities, alogia, 
blunted affect, anhedonia, and avolition. In the present 
study, there was no significant change in sustained atten-
tion, and the decrease in nonperseverative errors observed 
over a short period of 8 weeks was closely associated 
with test motivation. Clinical symptoms and cognitive 
functioning were improved dramatically at T1. This find-
ing further demonstrated that the alleviation of psychotic 
symptoms influenced test performance. Nevertheless, one 
study that evaluated the cognitive functions of patients 
with schizophrenia for five years suggested that impro-
vements in cognitive domains were associated with a 
decrease in positive symptoms but unrelated to negative 
symptoms. Thus, the relationship between clinical symp-
toms and cognitive functioning remains elusive.
15 
Changes in cognitive functioning emerged selectively in 
this study. That is, even if a patient’s clinical symptoms 
improved, other cognitive functions, such as sustained 
attention and executive functions (except for nonperse-
verative errors on the WCST), did not show significant 
improvement. In fact, the results of the present study 
consistently demonstrated that a deficit in sustained at-
tention was the main course of cognitive disturbance in 
patients with schizophrenia. Our results partially sup-
ported the idea that symptoms and cognitive functions 
are independent,
10 and the cognitive functions of patients 
with schizophrenia are aggravated over time.
45 
The total number of errors on the WCST and immediate 
list recall component of the K-MAS were predictive of 
treatment response. Total errors on the WCST were a 
better predictor of treatment response than immediate 
list recall. Total errors included both perseverative errors 
and nonperseverative errors. The number of perseverative 
errors served as a reflection of difficulty in shifting cog-
nitive sets according to various conditions. The number 
of perseverative errors was considered to be a significant 
cognitive variable for predicting patient relapse after 
their first episode.
19 
Similarly, perseverative errors also indicated that a 
perseverative response was a vulnerability indicator of 
schizophrenia.
46 Social function has been related to so-
cial cognition,
47 which may include emotional perception, 
social schema, insight, and coping strategies. Basic neu-
rocognitive functions are required in order to understand 
the emotions of other people. If emotional perception abi-
lity is diminished, interpersonal relations prove be dif-
ficult.
48 These data support that the effort to identify cog-
nitive domains that can predict treatment response is of 
importance, as executive function is closely related to 
social adjustment. 
The responders showed lower performance in terms of 
cognitive function, especially executive function, than 
the non-responders at T0. They also showed a longer 
duration of illness. It seems that as schizophrenia epi-
sodes repeat, the treatment response diminishes, and schiz-
ophrenia patients become recalcitrant to treatment and 
recovery.
49,50 Therefore, the duration of illness influences 
the treatment response and cognitive performance. The 
cognitive functions of non-responders were mildly ag-
gravated over time, regardless of treatment intervention. 
Unlike the responders, the non-responders failed to show 
improvement in clinical symptoms. Therefore, the im-
provement in clinical symptoms and clinical deficits that 
can be achieved by drug therapy is limited. 
There were several methodological limitations of the 
present study. First, the subjects included in the present 
study were patients hospitalized in a specific psychiatric 
ward rather than patients from the local community. There-
fore, our results may not be applicable to the entire po-
pulation of persons suffering from schizophrenia. Second, 
we limited our comparison to patients with schizophrenia 
and normal controls. 
To determine whether cognitive deficits implicated in 
schizophrenia are specific or represent other clinical vari-
ables, it is necessary to compare patients with schizo-
phrenia to those with other mental disorders in a future 
study. A third limitation is that the subjects included in 
the present study were mostly paranoid schizophrenics 
with prominent positive symptoms. 
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